 |
Video: What is a Stock Split?
|
 |
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. Co.'s pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGF? expressed on cancer cells. Its pipeline also includes CRB-913, which is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has in-licensed the intellectual property for CRB-601 from Dr. According to our CRBP split history records, Corbus Pharmaceuticals Holdings has had 1 split. | |
 |

Corbus Pharmaceuticals Holdings (CRBP) has 1 split in our CRBP split history database. The split for CRBP took place on February 14, 2023. This was a 1 for 30 reverse split, meaning for each 30 shares of CRBP owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 33.3333333333333 share position following the split.
When a company such as Corbus Pharmaceuticals Holdings conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the CRBP split history from start to finish, an original position size of 1000 shares would have turned into 33.3333333333333 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Corbus Pharmaceuticals Holdings shares, starting with a $10,000 purchase of CRBP, presented on a split-history-adjusted basis factoring in the complete CRBP split history.

Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
06/23/2015 |
|
End date: |
06/20/2025 |
|
Start price/share: |
$94.80 |
|
End price/share: |
$8.24 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-91.31% |
|
Average Annual Total Return: |
-21.67% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$869.52 |
|
Years: |
10.00 |
|
|
 |
Date |
Ratio |
02/14/2023 | 1 for 30 |
|
 |